NVAX (Novavax Pharma) Projected Price to Earnings

Official company branding of Novavax Corp (NVAX)

Novavax, Inc. (NVAX) bet on developing combined influenza and COVID vaccines is reflected in the dynamics of the company's forward P/E ratio, where the value of 0.00 expresses the metric level. However, the post-pandemic revenue collapse has eliminated cash flow predictability. The business currently relies critically on the commercialization of new product lines and aggressive cost restructuring for survival.

NVAX - Novavax Market Cap to Projected Earnings over the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Novavax, Inc.

- current price and projected stock value:
Stock Quotes Novavax Corp|NVAX - Fair Value Consensus
- business market valuation indicators:
Market Valuation Novavax Pharma|NVAX - Total Company Value
- issuer book value statistics:
Book Value per Share Novavax|NVAX - Book Valuation of Business|Market Value to Book Value Ratio novavax.com|NVAX - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Novavax, Inc.|NVAX - Long-Term Debt to Capital|Short-Term Debt to Equity Novavax Inc|NVAX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Novavax, Inc.|NVAX - Company Long-Term Indebtedness|Company Short-Term Debt Novavax|Quick Liquidity Indicator novavax.com
- earnings and market ratios statistics:
NVAX - Company Net Income|Projected Future Earnings Novavax, Inc.|NVAX - P/E Multiple|Projected Price to Earnings Novavax, Inc.|NVAX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Novavax Corp|NVAX - Operating profit EBITDA|Net earnings per share for the last 12 months Novavax|NVAX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months novavax.com|NVAX - Earnings per share increase in current year|Earnings growth forecast for next year Novavax, Inc.
- revenue and sales proceeds data:
NVAX - Company Gross Revenue|Company Projected Revenue Novavax, Inc.|NVAX - Market Cap to Revenue Ratio|Forward P/S Multiple Novavax
Basic company analysis:NVAX Novavax, Inc.
Product sample of Novavax, Inc.

Novavax, Inc. (NVAX) maintains a strong position due to streamlined global logistics and seamless drug distribution. The company's forward P/E ratio compares current market value with expected net income for the coming year. This indicator allows investors to assess the extent of the premium paid for future earnings. By analyzing this chart, one can determine the optimal entry point into the asset. A low multiple confirms the fundamental stability of the business.

Who Novavax, Inc. competes with

Projected Price to Earnings GILD (Gilead Sciences Inc)|CDTX (Cidara Therapeutics, Inc.) - Future Price to Earnings Multiple|CureVac N.V. - Projected Price to Earnings|Valneva SE - Future Price to Earnings|VIR - Future Price to Earnings|Market Cap to Projected Earnings SIGA Technologies Inc SIGA|EBS (Emergent BioSolutions Inc) - Projected Price to Earnings|Atea Pharmaceuticals - Future Price to Earnings Multiple|Projected Price to Earnings IVVD|Forward P/E Multiple enanta.com|Forward P/E Multiple INO|Market Cap to Projected Earnings HilleVax|Future Price to Earnings Kalaris Therapeutics Inc. KLRS|DYAI: Price to Future Earnings Ratio|NanoViricides, Inc. - Forward P/E Multiple|TLPH - Forward P/E Multiple|COCP: Forward P/E Multiple|Traws Pharma, Inc. (TRAW) - Forward P/E Multiple|Projected Price to Earnings DWTX|Future Price to Earnings QLGN|Projected Price to Earnings ALVR (AlloVir)|Future Price to Earnings VBIV (VBI Vaccines)|Future Price to Earnings virios.com VIRI|Market Cap to Future Earnings Ratio VXRT (vaxart.com)